Fig. 3: Activity of marketed and experimental antimalarials in sporozoite viability, gliding, traversal, and hepatic schizogony assays. | Communications Biology

Fig. 3: Activity of marketed and experimental antimalarials in sporozoite viability, gliding, traversal, and hepatic schizogony assays.

From: Assessment of the drugability of initial malaria infection through miniaturized sporozoite assays and high-throughput screening

Fig. 3

Compounds were tested against P. falciparum NF54 parasites using hepatocyte donor HC10-10 in the liver-stage assays. The figure shows percentage viability, gliding motility, cell traversal capacity, and a number of liver-stage parasites relative to the vehicle controls (0.1% DMSO). Compounds were tested at 10 µM except for the liver-stage assay, where compounds were assayed at 5 µM. The figure shows average data from two independent experiments with two replicates per experiment. Spz: sporozoite, DHA: dihydroartemisinin, PI4K: phosphatidylinositol 4-kinase, ATP4: P-type Na+ adenosine 5’-triphosphatase 4, BC1: coenzyme Q: cytochrome c–oxidoreductase, DHODH: dihydroorotate dehydrogenase, CARL: cyclic amine resistance locus, EF2: elongation factor 2, HMT: histone methyl transferase, NMT: N-myristoyl transferase.

Back to article page